What you'll find here at MDLinx Rheumatology: The top rheumatology clinical articles of the day, plus MDLinx exclusive content
Your Unread Messages in Rheumatology
See All >> Messages include industry-sponsored communications and special communications from MDLinx
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage
Smartest Doc Challenge
MDLinx
Clinical Pearls for Rheumatologists
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
D Scott Cunningham MD, PhD
Site Editor, MDLinx
MMP-3 and COMP predict PsA response to TNF inhibitors
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
981 Evidence-Based Soft Tissue Rheumatology: Epicondylitis and Hand Stenosing Tendinopathy JCR: Journal of Clinical Rheumatology, March 24, 2004
982 Email triage of new neurological outpatient referrals from general practice Practical Neurology, March 17, 2004
983 How to avoid being sued in clinical practice Postgraduate Medical Journal, March 12, 2004
984 Laboratory Tests in Adults with Monoarticular Arthritis: Can They Rule Out a Septic Joint? Academic Emergency Medicine, March 10, 2004
In a study involving 74 patients with juvenile idiopathic arthritis (JIA), 26 patients had detectable anti-citrullinated protein antibodies (ACPA). The ACPA titers correlated with disease progression at baseline and after a median follow-up of 11.5 months. In addition to predicting disease severity and progression, the authors concluded that ACPA were superior to IgM-RF in diagnosing JIA.
Read the article summaryIn a study involving 208 patients with SLE followed for 12 years, 42 deaths occurred, 48% of which were considered to be cardiovascular mortalities. Age, increased cystatin C levels, and arterial disease were predictive of all-cause mortality. Cigarette smoking and increased sVCAM-1, hsCRP, abeta2GP1, and aPL antibody levels were predictive of cardiovascular mortality.
Read the article summaryIn a study conducted at the University of Geneva involving 118 patients with rheumatoid arthritis, but without cardiovascular disease at baseline, the 10-year Framingham cardiovascular risk score (FRS) was improved with the inclusion of the anti-apoA-1 antibody titer. The median follow-up was 9 years and the incidence of cardiovascular disease was 16%. Other biomarkers, including the NT-proBNP, oxLDL, CRP, and RF levels and the anti-citrullinated peptide antibody titer, did not improve the FRS.
Read the article summaryIndexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatology more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close